When conviction collapses inside the VC partnership
How internal debate quietly downgrades deals founders think are progressing
Dear Readers,
In the previous edition of the HealthVC, we examined what gets written about you after you leave the room. We analysed how the Series A investment committee memo functions as a classification device and how durability increasingly anchors underwriting logic in 2026.
This week, we go further inside.
Even when a memo is written with enthusiasm, conviction is not final. It must survive internal debate. And it is inside that debate where many strong Series A processes quietly unravel.
From the outside, nothing appears dramatic. Meetings continue. Feedback remains constructive. No one explicitly rejects the company. Yet leadership hesitates. Timelines stretch. Terms soften. Momentum dissipates.
Conviction rarely collapses in a single moment. It fragments under pressure.
Understanding how that fragmentation occurs is critical if you are raising in the current environment.
Conviction is individual before it is institutional
Every Series A process begins with individual conviction. A partner sees something compelling. They construct a thesis. They invest time. They begin drafting the memo.
That initial conviction is personal.
Institutional conviction is different.
Institutional conviction must survive disagreement.
Inside a partnership, different partners weigh risk differently. One may prioritise upside asymmetry. Another may anchor on capital preservation. A third may be acutely sensitive to reserve intensity relative to fund size. These differences are healthy, but they create variance in how fragility is perceived.
When a deal is structurally robust, that variance collapses quickly into alignment.
When a deal contains ambiguity, variance amplifies.
The purpose of the IC meeting is not to celebrate the thesis. It is to interrogate it.
And interrogation exposes structural tightness.
The mechanics of internal doubt amplification
Conditional language inside the memo becomes leverage during debate.
If the memo states that growth is strong but early in repeatability, someone will ask what happens if repeatability takes longer to stabilise. If burn is described as aligned with projected milestones, someone will ask how elastic that burn truly is under delayed revenue. If the capital trajectory assumes a Series B within eighteen months, someone will model what happens if that window extends to twenty-four.
Each question appears reasonable.
Collectively, they change classification.
To illustrate, consider a simulated internal exchange.
The champion opens by framing the company as a category-defining opportunity with compelling traction and a credible path to €12 million ARR within twenty-four months. The growth rate is seventy percent year-on-year. Gross margins exceed seventy-five percent. The round size is €14 million.
A partner asks whether the €12 million ARR target assumes current sales velocity persists. The champion acknowledges that velocity may moderate but emphasises strong pipeline visibility.
Another partner extends enterprise sales cycles in their mental model from six months to nine. Under that adjustment, ARR at month eighteen falls short of the inflection point assumed in the base case. Runway compresses from nineteen months to fifteen.
A third partner raises reserve modelling. If the fund takes twenty percent ownership at entry, what does maintaining that stake through Series B require if valuation expansion is modest. Under conservative assumptions, defending ownership may require €10 to €15 million in follow-on capital.
The room shifts.
The deal is no longer simply about category leadership. It becomes about capital exposure under moderated execution.
No one rejects the company.
But someone says, “Perhaps we participate rather than lead.”
That sentence marks the downgrade.
Reserve intensity as a hidden fault line
Reserve modelling is often the decisive inflection point in internal debate.
Most Series A funds allocate approximately forty to sixty percent of total fund capital to reserves. That capital must support multiple portfolio companies across different timelines.
When evaluating a new investment, partners model entry ownership, dilution scenarios, and expected participation in future rounds under both base and conservative cases.
Consider a €200 million fund targeting fifteen core positions with a fifty percent reserve ratio. Approximately €100 million is available for follow-on deployment. If one new Series A allocation implies potential follow-on exposure of €15 million under conservative modelling, that single company represents fifteen percent of the reserve pool.
Even if the upside is compelling, reserve concentration becomes material.
If three such companies exist simultaneously, reserve flexibility compresses rapidly.
This is why capital intensity matters more in 2026.
It is not a moral judgment about ambition. It is portfolio mathematics.
When reserve burden feels disproportionate relative to risk-adjusted upside, leadership appetite weakens.
Founders rarely see this debate. They feel it through hesitation.
The tipping point from enthusiasm to caution
Conviction collapse is rarely dramatic. It is incremental.
Language shifts from “we should lead” to “we should stay close.” Ownership targets soften. A partner suggests waiting for one additional quarter of data. Someone proposes syndicating leadership.
Each adjustment is rational.
Collectively, they reclassify the deal.
Once reclassified as conditional, momentum deteriorates externally as well. Other funds sense hesitation. Signalling weakens. Negotiating leverage declines.
The founder often responds by increasing urgency. They compress timelines. They amplify signalling. They attempt to manufacture scarcity.
Scarcity does not repair structural hesitation.
Structural hesitation originates in three places: downside elasticity, reserve intensity, and repeatability ambiguity.
Unless those are addressed directly, conviction rarely reconsolidates.
At this point, many founders misinterpret feedback. They assume the issue is traction volume rather than fragility perception. They attempt to increase growth rather than reduce ambiguity.
The deeper intervention is different.
And that is where paid HealthVC begins.